Find a Doctor or Practice Location

1.Management of patients with Non-Hodgkin's lymphoma, Hodgkin's Lymphoma, multiple myeloma, acute and chronic leukemias with standard therapy as well as clinical experimental therapies using new agents.
2. Bone Marrow and Stem Cell Transplantation, autologous and allogeneic.
3. Special interest in treating patients with aggressive non-Hodgkin's lymphoma, lymphoma in the elderly and lymphoma in the pregnant patient.
4. Special interest in the long-term follow-up of patients with Hodgkin's lymphoma and survivors issues.

Medical School: Virginia Commonwealth University
Residency: Baylor College of Medicine - Ben Taub General Hospital
Residency: Baylor College of Medicine/Texas Children's Hospital
Fellowship: Baylor College of Medicine/Texas Children's Hospital
Fellowship: University of Texas - MD Anderson Cancer Center
Fellowship: University of Texas Hospitals

American College of Physicians, National American Medical Association, National American Society of Clinical Oncology, National American Society of Hematology, National Leukemia and Lymphoma Society, National

Hospital Privileges:

• Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.

Description of Research Expertise:

Clinical trials in non-Hodgkin's lymphoma, phase I, II and III

Selected Publications:

Hivnor CM, Nguyen V, Rook AH, Junkins-Hopkins J, Gelfand JM, Nasta S, Frank I, Kim EM: CD8+ lymphoma in a patient with human immunodeficiency virus Archives of Dermatology 141 (10): 1321-2,2005.

Tsai DE. Aqui NA. Vogl DT. Bloom RD. Schuster SJ. Nasta SD. Wasik MA.: Successful treatment of T-cell post-transplant lymphoproliferative disorder with the retinoid analog bexarotene. American Journal of Transplantation. 5 (8): 2070-3,2005.

Vogl DT. Glatstein E. Carver JR. Schuster SJ. Stadtmauer EA. Luger S. Nasta SD. Porter DL. Elstrom R. Tsai DE.: Gemcitabine-induced pericardial effusion and tamponade after unblocked cardiac irradiation. Leukemia & Lymphoma 46 (9): 1313-20,2005.

Loren AW. Luger SM. Stadtmauer EA. Tsai DE. Schuster S. Nasta SD. Goldstein SC. Perl A. Orloff G. Oliver JC. Green J. Emerson SG. Porter DL.: Intensive graft-versus-host disease prophylaxis is required after unrelated-donor nonmyeloablative stem cell transplantation. Bone Marrow Transplantation 35 (9): 921-6,2005.

Tsai DE. Maillard I. Downs LH. Alavi A. Nasta SD. Glatstein E. Schuster SJ.: Use of iodine 131I-tositumomab radioimmunotherapy in a patient with Waldenstrom's macroglobulinemia. Leukemia & Lymphoma 45 (3): 591-5,2004.

Nasta SD, Hoff PM, GeorgeCM, Neubauer, M, Cohen SC, Abbruzzese JA, Winn R., Pazdur RM: “Phase II Study of MGI-114 Administered Intravenously for Five Days Every 28 Days to Patients with Metastatic Colorectal Cancer” AJCO 26 (2): 132-134,2003.

Nasta SD, Carrum G., Shahab I., Hanania N, Udden MM: “Regression of a Plasmablastic Lymphoma in a Patient with HIV on Highly Active Antiretroviral Therapy” Leuk Lymphoma 43 (2): 423-426,2002.

Cohen AD, Luger SM, Sickles C, Mangan PA, Porter DL, Schuster SJ, Tsai DE, Nasta S, Gewirtz AM, Stadtmauer EA: “ Gemtuzumab ozogamicin (Mylotarg) monotherapy for relapsed AML after hematopoietic stem cell transplant: efficacy and incidence of hepatic veno-occlusive disease" Bone Marrow Transplant 30 (1): 23-28,2002.

Dwivedy, S: “Hodgkin’s Disease: Clinical Management and Future Perspectives” Fellows Reporter 6 (3): 2001.

Dwivedy S,. Hoff P. M, Dumas P.,. Lassere Y,. Aguayo A,. Hayakawa T, Abbruzzese J.L.: Safety and phamacokinetics (PK) of an antitumor/antiangiogenic agent, TAS-102: a phase I study for patients(pts) with solid tumors ASCO : 2001.

Penn Cancer Services